All of this may be because pituitary resuscitation was in the luteal phase, and 6–7 weeks after the administration of depot GnRH-a, any detrimental effect on the luteal phase was thus increasingly weak; therefore, there may be no need for stronger corpus luteum support, and clinicians should be vigilant against the elevated risk of moderate or severe OHSS compared to that in the long protocol. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.